The difference of CA19-9 and CEA levels between healthy controls and early-stage cervical cancer patients was found not significant (p = 0.71 and 0.17, respectively), indicating that CA19-9 or CEA alone cannot discriminate early-stage cervical cancer patients from healthy controls. The gene discussed is CEACAM5; the disease is cervical cancer.